Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1020368 | 0.98 | NPC1 (0.48) | NPC1ALDH1A1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL625354 | 0.94 | NPC1 (0.44) | NPC1ALDH1A1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL30929543 | 0.90 | HDAC4 (0.41) | NPC1ALDH1A1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL1769351 | 0.90 | HDAC4 (0.41) | NPC1ALDH1A1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL5138689 | 0.87 | HDAC4 (0.46) | NPC1ALDH1A1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL30338086 | 0.81 | OPRM1 (0.37) | NPC1ALDH1A1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL4006359 | 0.81 | ALDH1A1 (0.37) | NPC1ALDH1A1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL18742752 | 0.81 | HDAC4 (0.44) | NPC1ALDH1A1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL615034 | 0.81 | OPRM1 (0.37) | NPC1ALDH1A1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL10389492 | 0.81 | ALDH1A1 (0.41) | NPC1ALDH1A1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-8431590-B2 | Spiroindolines as modulators of chemokine receptors | GLAXO GROUP LIMITED (GB) | 2013-04-30 | — | — | US | disclosed |
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| US-20110034499-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2011-02-10 | — | — | US | disclosed |
| EP-2094677-B1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | REMYND NV (BE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| EP-1981504-B1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | REMYND NV (BE) | 2010-07-21 | — | — | EP | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
| US-7595338-B2 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | WYETH (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595338-B2 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | WYETH (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595338-B2 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | WYETH (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| EP-2094677-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV Remynd (BE) | 2009-09-02 | — | — | EP | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
| EP-1877377-A2 | PROCESS FOR PREPARING 3,3-DISUBSTITUTED OXINDOLES AND THIO-OXINDOLES | Wyeth (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006118955-A2 | PROCESS FOR PREPARING 3,3-DISUBSTITUTED OXINDOLES AND THIO-OXINDOLES | WYETH (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060247441-A1 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | WYETH (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | NPC1 77/4885ALDH1A1 1930/4885RAB9A 2845/4885 |
| US-20060247441-A1 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | TPMT, TH, HTR3C | NPC1 4132/4885ALDH1A1 1493/4885RAB9A 2231/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | NPC1 77/4885ALDH1A1 1930/4885RAB9A 2845/4885 |
| US-20110034499-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CCR10, CXCR2 | NPC1 620/4885ALDH1A1 1311/4885RAB9A 1738/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | NPC1 77/4885ALDH1A1 1930/4885RAB9A 2845/4885 |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | SNCA, PARK7, PRNP | NPC1 777/4885ALDH1A1 608/4885RAB9A 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.